

Public Health Link

From the Chief Medical Officer for Wales

Distribution:	As Appendix 1
From:	Andrew Evans, Directorate of Health Policy
Date:	18 September 2018
Reference:	CEM/CPhA/2018/15
Category:	Class 4: For information
Title:	Drug Alert Class 4, For Information, Cadiusun Pharma GmbH, Caspofungin 70mg Powder For Concentrate For Solution For Infusion
What is this about:	
Full details are set out below.	
Why has it been sent:	For your information and to pass on to Colleagues

Issue:

We have been informed that there are errors in the text on both the SPC and Patient Information Leaflet for this product.

Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website <https://www.gov.uk/drug-device-alerts>

We understand that this product is used in hospitals and is unlikely to be used in General Practice or Community Pharmacy. Please do not send this communication to Community Pharmacists or to GPs unless they are known to use the product outside the hospital setting.

To: NHS Wales Shared Services Partnership to forward to:

All General practitioners - please ensure this message is seen by all practice nurses and non-principals working in your practice and retain a copy in your 'locum information pack'.

All Community Pharmacists

Deputising services

HB Chief Pharmacists

HB Prescribing Advisers

Independent/Private clinics and Hospitals and Hospices throughout Wales

Community Optometrists

To: Chief Executives of Health Boards

To: Medical Directors of Health Boards

To: Nurse Directors Health Boards

To: Directors of Public Health

To: Hospital Principals and Chief Pharmacists to action as per alert

cc: Public Health Wales

Consultants in Pharmaceutical Public Health

Chief Executives, NHS Trusts

Principal Pharmacist Welsh Quality Control

Principal Pharmacist Continuing Care Services

Principal Pharmacist Welsh Medicines Information Centre

CSSIW

NHS Direct



DRUG ALERT

CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use
Distribute to Pharmacy and Ward Level

Date: 18 September 2018

EL (18)A/15

Our Ref: MDR 11-09/18

Dear Healthcare Professional,

Cadiusun Pharma GmbH

**Caspofungin 70mg powder for concentrate for
solution for infusion**

PL 42069/0003

Batch Number	Expiry Date	Pack Size	First Distributed
180524AD	04/2020	1 x vial	19/07/2018
180530AD	04/2020	1 x vial	n/a

Cadiusun Pharma GmbH has informed us that there is an error on the patient information leaflet for the above product.

The error is on the portion of the leaflet which is intended for Healthcare Professionals, in the sections providing instructions for preparation of both 70mg/m² and 50mg/m² infusion for paediatric patients > 3 months of age. In the incorrect version of the leaflet, the final concentration of the solution is given as 5.2mg/ml for both dilutions. **The correct final concentration is 7.2mg/ml, however**

In addition to the error on the Patient Information Leaflet, there is also an error on the Summary of Product Characteristics for the product. The heading for preparation of the 70mg/m² infusion for paediatric patients > 3 months and the heading for preparation of the 50mg/m² infusion for paediatric patients > 3 months incorrectly state in brackets 'using a 50-mg vial'. **The headings should read as follows:**

Preparation of the 70 mg/m² infusion for paediatric patients > 3months of age (using a 70-mg vial)

Preparation of the 50 mg/m² infusion for paediatric patients > 3months of age (using a 70-mg vial)

Steps have already been taken to correct the errors on both the patient information leaflet and the Summary of Product Characteristics.

Please note, the patient information leaflet and Summary of Product Characteristics for the 50mg presentation of the product are correct.



Medicines & Healthcare products
Regulatory Agency



Date: 18 September 2018

EL (18)A/15

Our Ref: MDR 11-09/18

For medical information enquiries on this matter, please contact Tillomed Medical Information, email pvuk@tillomed.co.uk

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Please ensure that it is passed on to paediatric wards if the product is prepared on site.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574